Dr. Yi Lin is a professor of medicine with joint appointment in the Division of Hematology and Experimental Pathology at Mayo Clinic, Rochester, Minnesota.  Her practice is in lymphoma and myeloma.  She has an NIH-funded laboratory and clinical research program in biomarkers and immunotherapy. She is the PI and co-PI of multiple clinical trials testing novel dendritic cell vaccine combination immunotherapy and CAR-T therapy.  She is the medical director for the Immune Effector Cell Program at Mayo Clinic, Rochester. As the Mayo Clinic Comprehensive Cancer Center Enterprise Leader of Cancer Regenerative Biotherapeutics, she also oversees the cancer cell therapy clinical research portfolio and practice across all three Mayo sites in Minnesota, Arizona, and Florida. She is also the Associate Medical Director of Mayo Clinic Center for Regenerative Biotherapeutics. She also co-chairs the International Myeloma Working Group (IMWG) Novel Immunotherapy Steering Committee and co-chairs the Society for Immunotherapy of Cancer (SITC) Myeloma Cancer Immunotherapy Guideline Subcommittee.